

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

DIALOG(R)File 16:(c) 2001 The Gale Group. All rts. reserv.

06269455 Supplier Number: 543-8756 (USE FORMAT 7 FOR FULLTEXT)
New industry trends are reviving interest in this natural ingredient.
April, 1999
Word Count: 1484

... Shea butter has always served as a staple of African pharmacology. It acts as an effective decongestant, for example. Used for its draining and anti-*inflammatory* properties, it is soothing in sprains and strains, and

is a widely used anti-inflammatory agent. This wonderful healing agent is also used for

...Shea fruit is harvested and the butter is made in an African village.
Botanical Aspects

A hardy tree not native to Africa, the Shea tree (*Butyrospermum* *parkii* Kotsch) grows to 20 meters high. It usually lives for a couple of centuries, covering vast areas. The dark green foliage is...hour and persists for eight hours. For subjects, a daily application maintains a very good moisture level of the superficial layers of the skin.

Anti-*inflammatory* properties

Shea butter is traditionally used for alleviating rheumatism, which suggests an anti-*inflammatory* property. This has been substantiated (Tella) in a study of severe nasal congestion. Shea butter is tested on 33 volunteers against congestion and is found to be containing...

...Pharmacopoeia), a natural product.

Nasal congestion is a condition that can be relieved by two mechanisms: a vasoconstrictor and an anti-*inflammatory*. Only the second mechanism applies for Shea butter, which has never demonstrated any vasoconstricting activity.

Efficient Release of Active Ingredients

This study (K...)

2/6,K/2 (Item 2 from File 15)

DIALOG(R)File 16:(c) 2001 The Gale Group. All rts. reserv.

04595691 Supplier Number: 543-8756 (USE FORMAT 7 FOR FULLTEXT)
Protecting skin and preventing
Oct, 1996
Word Count: 1592

... is concerned that the use of tanning agents encourages users to stay in the sun longer, increasing exposure to ultraviolet radiation and also increasing the risk of an *allergic* reaction to the active ingredients. This may be why more *allergies* to PABA derivatives have been reported.

With the number of UV filters permitted for use in cosmetics restricted to relatively few synthetic materials, attaining ever higher...that acts as a free radical scavenger. Other natural ingredients that are in use include...tanned vegetable oils, tocopheryl acetate, inatanil... *parkii* (Shea Butter) and Shea Butter Unsaponified.

Melanin continues to be a primary ingredient in suncare products and Titanium Dioxide has produced a...incorporating it. A...

...pH of 5-9. It is claimed to provide a natural-look tan on mammalian skin and...anti-inflammatory* hypo- and hyperpigmentation.

Finally, for those who want to protect their skin from ultraviolet... Ciba-Geigy has developed a...ultraviolet...

2/6,K/3 (Item 1 from File 15)

DIALOG(R)File 53:(c) 2001 The Gale Group. All rts. reserv.

00876886 FOODLINE ACCESSION NUMBER: 547093

Composition containing extracts of *Butyrospermum parkii* and the use as medicament or dietary supplement.

PATENT: WO 0103712

Composition containing extracts of *Butyrospermum parkii* and the use as medicament or dietary supplement.

ABSTRACT: A composition comprising an extract or concentrate of *Butyrospermum parkii* is useful as a dietary supplement or medicament for the suppression of hypersensitivity and/or inflammatory diseases. The active components include stigmasterol, avasterol, 24-methyl-cholesterol, karitesterol A, karitesterol B and alpha-spinasterol.

DESCRIPTORS: BUTYROSPERMUM PARKII EXTRACT...

...HYPERSENSITIVITY*; INFLAMMATORY DISEASES

2/6,K/4 (Item 1 from file 148)
DIALOG(R) File 73: (c) 2001 Elsevier Science B.V. All rts. reserv.

01451701 EMBASE No: 1979
Preliminary studies on nasal decongestant activity from the seed of the shea butter tree, *Butyrospermum parkii*
1979

Preliminary studies on nasal decongestant activity from the seed of the shea butter tree, *Butyrospermum parkii*

The seed of *Butyrospermum parkii* yields shea butter which according to local traditional healers is useful for the treatment of inflammation of the nostrils. Since there is as yet no absolutely satisfactory nasal decongestant in clinical use, it was decided to investigate the effects of shea...

2/6,K/5 (Item 1 from file 148)
DIALOG(R) File 148: (c) 2001 Elsevier Science B.V. All rts. reserv.

09324537 SUPPLIER NUMBER: 1326 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Protecting skin and preventing melanoma (sun protection products)
Oct, 1996
WORD COUNT: 1814 LINE: 52

... is concerned with encouraging users to stay in the sun longer, increasing the risk of skin cancer and also increasing the risk of an allergic reaction to the active ingredients. This may be why more allergies to PABA derivatives are reported.

With the number of UV absorbers permitted for use in cosmetics restricted to relatively few established materials, attaining ever higher ... that acts as a free radical scavenger. Other natural ingredients that are in use include waxes, saturated vegetable oils, tocopheryl acetate, rhamnose, and shea butter. *Butyrospermum parkii* (Shea Butter) and Shea Butter Unsaponifiables.

Melanin continues to be a major concern for manufacturers of sun-care products and Tioxide has produced a new generation of pigments for...

... pH of 5-9. It is claimed to be useful for providing a natural-look tan on mammalian skin and hair, and for the treatment of post-inflammatory hypo- and hyperpigmentation. (10)

Finally, for those who choose to use a sunscreen on their skin, Ciba-Geigy has recently developed a new generation of sunscreens.

2/6,K/6 (Item 2 from file 148)
DIALOG(R) File 148: (c) 2001 The Gale Group. All rts. reserv.

07518215 SUPPLIER NUMBER: 15790712 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Cosmetic use of selected natural fats and oils.
August, 1994

antioxidants, astringents, emulsifiers, antiseptics, antistatic agents, antringents, binders, buffers, additional carriers, chelators, cell stimulants, cleansers, conditioners, deodorants, dipilatories, detergents, disinfectants, emollients...

00588650

AGENTS DE SOIN POUR LA PEAU
HAUTPFLEGE MITTEL

Claims

Publication Year: 1998

Detailed Description

...and 10 well prepared according to the invention 100% of the skin and significantly reduce the release of mediators.

...0,1 et 10 % en poids. Les compositions permettent de renforcer la tonicité de la peau tout en limitant sensiblement l'agitation de médiateurs pro-inflammatoires.

... and 10 ... the
the invention increases the ... skin and significantly reduce
the release of pro-infl ... (57) Zusammenfassung
Kosmetische Zusammensat ... empfindlicher Haut in Form von
Emulsionen oder Cremes ... oder -komponenten natürliche
Ole, Fette, Wässer ... S-75 : Hydrogenated
Lecithin M ... et ...
Soy Sterol ... et ...
Trihydro ... - ...
*Butyrol ... Cation ...
318 Capryl/Capric ... : Cetylaryl Isononamooate Tufskin
: Sorbitol und Yes ... Bio:accharide Gum (reich an...

013654043

WPI Acc No: 2001-13825

Title Terms: PHASE; [?]; [?]; [?]; [?]; COMPREISE; TREAT;

*HYPERSENSITIVITY

Pharmaceutical e.g. for immunomodulation or anti-inflammatory effects

Butyrospermum *parkii*

inflammatory or

Abstract (Last 6) :

... Pharmaceutical Corp. s. Non-er dietary supplement comprising an

extract or concentrate of *Butyrospermum parkii*, is new.

... i) an extract or concentrate of *Butyrospermum parkii* containing at least 5% (w/w) of Butyrospermum-triterpene fraction comprising (by w/w):

...An INDEPENDENT CLAIM is also included for a method for the preparation of the pharmaceutical composition comprising *Butyrospermum parkii*.

...The pharmaceutical composition in the form of a medication or dietary supplement is useful for the stimulation or suppression of hypersensitivity and allergic reactions (e.g. of the skin or mucous membranes) and for preventing autoimmune diseases and conditions (such as psoriasis, atopic dermatitis, Crohn's disease, ulcerative colitis, osteoarthritis), for alleviating pain or for preventing or treating prostatitis or benign prostatic hypertrophy. In addition, the composition may also be useful for treating or preventing E mediated allergic reactions and conditions diabetes mellitus, multiple sclerosis, autoimmune hemolytic anemia, infections (e.g. viral or fungal), transplant rejection and asthma.

Technology Focus:

... Preparation of a composition of *Butyrospermum parkii* is mixed with a pharmaceutically acceptable carrier, and comprises up to 100% (w/w) (i) Butyrospermum triterpene fraction comprising (by w/w) (a) 10-40.

...Title Terms: *HYPERSENSITIVITY*; *INFLAMMATION*;

2/6,K/21 Item File
DIALOG(R)File 051: ... reserv.

013051688

WPI Acc No: 2000-22 2/2 0.

Title Terms: COSMETIC COMPOSITION; NOTHING; SKIN; REDUCE; *INFLAMMATION*;
LINE; WRINKLE; COMB; FREE; RADICAL; CONTAIN; GREEN; COFFEE;
SHEA; BUTTER; EXTRACT

Cosmetic composition for skin care and reducing inflammation, lines and wrinkles. Contains free radicals, contains green coffee and shea butter extract.

Abstract (Basic):

... A new product is prepared from green coffee Coffea arabica L. and Shea butter from the nut of *Butyrospermum*.

... The product and Shea butter are useful for healing and soothing skin. The product has effects of oxygen free radicals, skin inflammation, redness, aging and drying, the appearance of wrinkles and hair loss. The product is used for the hair, scalp, nails, and mucosa (all skin).

...Title Terms: *INFLAMMATION*

2/6,K/22 Item File
DIALOG(R)File 051: 2000-22 2/2 0. reserv. All rts. reserv.

000969408

Title: COMPOSITIONS A USAGE COSMETIQUE OU DERMOPHARMACEUTIQUE CONTENANT UN MELANGE D'EXTRAIT DE CAFE VERTE ET DE BEURRE DE KARITE

Publication Date: 19991217

Abstract:

...vert Coffea arabica L. et du beurre de karité obtenu à partir de l'arbre à karité ou *Butyrospermum parkii* Kotschy. L'usage de ce produit dans des compositions à usage cosmétique ou dermopharmaceutique le produit résultant de cette

association est utilise en tant que tel ...

...et la recherche d'effets thérapeutiques cutanés, y compris contre les -
conséquences des effets toxiques des formes radicalaires de l'oxygène
comme, par exemple, l'inflammation cutanée, le vieillissement ou le
dessechement prématuré de la peau, l'apparition des rides, ainsi que pour
favoriser la protection des cheveux, du cuir chevelu...

2/6,K/23 (Item 1 from
DIALOG(R)File 377:(c) 2000 Ltd. All rts. reserv.

00607173 DERWENT ACCESS

A new African vegetable oil for the treatment of neurodermatitis and
other skin diseases (Radical-scavenging activity of *Butyrospermum parkii*, 1994

A new African vegetable oil for the treatment of neurodermatitis and
other skin diseases (Radical-scavenging activity of *Butyrospermum parkii*).

2/6,K/24 (Item 1 from 1 399
DIALOG(R)File 399:(c) 2000 AMERICAN MEDICAL SOCIETY. All rts. reserv.

Pharmaceutical composition comprising extracts of *Butyrospermum parkii*
and the use as medicament or dietary supplement

2/6,K/25 (Item 1 from 1 399
DIALOG(R)File 553:(c) 2000 Ltd. All rts. reserv.

04033339 H.W. M. (c) 1999 (USE FORMAT 7 FOR
FULLTEXT)

Shea butter (from *Butyrospermum parkii*).

Apr. '99

WORD COUNT: 2060

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

... Shea butter is a staple of African pharmacology.
It acts as an effective anti-inflammatory and anti-oxidant. Used for its draining
and anti-inflammatory properties, shea butter is used in sprains and strains,
and is a widely used anti-inflammatory agent. This wonderful healing agent
is also used for accelerated healing.

...Shea fruit is harvested in an African village.

BOTANICAL

A hardy tree, *Butyrospermum parkii* (Kotsch) grows in the savanna for a couple of
centuries, in the same place. The fruit is...hour and
persists for eight months. Daily application maintains a
very good moisture level in the epidermal layers of the skin.

ANTI-INFLAMMATION

Shea butter is used for treating rheumatism, which
suggests an anti-inflammatory effect. This has been substantiated
(Tella) in a study. Shea butter is tested on 33
volunteers against a placebo containing...

...Pharmacopoeia, 2nd ed.

Nasal congestion can be relieved by two
mechanisms: a vasoconstrictor or an anti-inflammatory*. Only the second
mechanism applies for shea butter. It has never demonstrated any
vasoconstrictor activity.

EFFICIENT RELEASE OF ACTIVE INGREDIENTS

8644206 Genuine Article#: 31113 Number of References: 14

Title: Separation of sterols and triterpene alcohols from unsaponifiable fractions of three plant seed oils

Author(s): Li JG; Ho CT (REPRINT); Li H; Tao HR; Liu LQ

Corporate Source: RUTGERS STATE UNIV, DEPT FOOD SCI, 65 DUDLEY RD/NEW BRUNSWICK//NJ/08901 (REPRINT); RUTGERS STATE UNIV, DEPT FOOD SCI/NEW BRUNSWICK//NJ/08901; BEIJING NORMAL UNIV, DEPT CHEM/BEIJING 100875//PEOPLES R CHINA/

Journal: JOURNAL OF FOOD LIPIDS, 2000, V7, N1 (MAY), P11-20

ISSN: 1065-7258 Publication Date: 20000500

Publisher: FOOD NUTRITION PRESS INC, 6527 MAIN ST, P O BOX 374, TRUMBULL, CT 06611

Language: English Document Type: ARTICLE

Geographic Location: USA; PEOPLES R CHINA

Subfile: CC AGRI--Current Contents: Agriculture, Biology & Environmental Sciences

Journal Subject Category: FOOD SCIENCE & TECHNOLOGY

Abstract: Preparative HPLC was used to separate sterols and triterpene alcohols from the unsaponifiable matters in plant oils from *Camellia weiningensis* L., *Brassica juncea* L. and *Micronia sikkimensis*. The isolated sterols and triterpene alcohols were acetylated and further purified by AgNO₃ impregnated silica gel preparative thin layer chromatography (TLC). The isolated acetyl derivatives of sterols and triterpene alcohols were identified by melting point, specific rotation, infrared and mass spectrometry. The sterols were brassicasterol, campesterol, stigmasterol, beta-sitosterol and Delta(5)-avenasterol, Delta(7)-avenasterol, Delta(7)-stigmastenol and alpha-spinasterol. The triterpene alcohols were cycloartanol, cycloartenol, 24-methylenecycloartanol cyclobranol, dammaradienol, tirucalla-7,24-dienol, **butyrospermol**, beta-**amyrin**, germanicol, Psi-4-taraxasterol and **lupeol**.

Identifiers--KeyWord Plus(R): VEGETABLE OILS

Cited References:

- BROOKS CJW, 1972, V20, P425, BIOLOGICAL
DEV S, 1989, V1, 131, CRC H-B TERPENOID
DEV S, 1989, V2, P75, CRC H-B TERPENOID
HELLER SR, 1978, HPLC IN FOOD ANALYSIS
HILL RA, 1991, DIET STEROLS AND LIPIDS
ITO H, 1973, V5, P1, J CHINESE U
ITO H, 1974, V6, P1, J CHINESE U
ITO H, 1980, V12, P1, J CHINESE U
LI H, 1998, V21, P1, J CHINESE U
LI H, 1997, V19, P60, J CHINESE U
RADT F, 1956, ELSEVIER'S PHYTOCHEMISTRY
RODD EH, 1953, P727, CHEM CARBON COMPOUND
UTSUMOYO T, 1983, V22, P789, PHYTOCHEMISTRY
YAN M, 1984, V5, P355, CHEM J CHINESE U

22/AB/1 (Item 1 from file: 155)

DIALOG(R)File 155:(c) format only 2001 Dialog Corporation. All rts. reserv.

The 4-monomethylsterol and 4,4-dimethylsterol fractions were separated from the unsaponifiables of 20 vegetable oils by preparative thin layer chromatography, and their compositions were determined by gas liquid chromatography. Tentative identification of the individual components of these fractions was carried out by gas liquid chromatography and combined gas liquid chromatography-mass spectrometry. Among 4-monomethylsterols, obtusifoliosol, graminol, and stigmasterol occur abundantly in most of the oils. Cyclooleucol occurs in some of the oils as a major component of 4-monomethylsterols. Among 4-monomethylsterols tentatively identified are: lophenol, 31-norcycloartenol, and 31-norlanostenol and/or lanostenol. Among 4,4-dimethylsterols, cycloartenol and 24-methylcycloartenol followed by beta-amyrin and cycloartanol are common in most of the oils. Butyrospermol, alpha-amyrin, lupeol, and cyclopentol together with a 4,4-dimethylsterol, presumably lanostenol, occur in some of the oils. Cycloclaudenol is present in poppy seed oil. Besides these compounds, each of the oils contains some unidentified members of 4-monomethylsterols and 4,4-dimethylsterols. The methylsterol fraction of capsicum seed oil as compared with that of the other oils is characterized by its very high content of lophenol and cycloartanol together with some other members, presumably 31-norlanostenol, 4alpha-methylcycloartanol, and lanostenol.

22/AB/2 (Item 1 from file: 34)

DIALOG(R)File 34:(c) 2001 Dialog Corporation. All rts. reserv.

Abstract: Site-directed mutagenesis was carried out on two triterpene synthases, beta-amyrin (PNY) and lupeol (OEW) synthases, to identify the amino acid residues responsible for their product specificity. In addition to sequence comparison among known oxidosqualene cyclase genes, chimeric studies suggested that (MWCYCR263)-M-256 sequence of beta-amyrin synthase PNY ((MLCYCR260)-M-255 sequence of lupeol synthase OEW) would participate in product differentiation. To test this hypothesis, Trp259 (MWCYCR of PNY) was mutated to Leu (PNY W259L mutant). Functional expression in yeast and product analysis revealed that this mutant produced lupeol as a major product together with beta-amyrin in 2:1 ratio. Some minor products including butyrospermol were also produced. The yeast strain carrying Leu256 (MLCYCR of OEW) was mutated to Trp (OEW L256W mutant). This mutant produced exclusively beta-amyrin as a major product together with lupeol, demonstrating that a single mutation could convert a beta-amyrin synthase into beta-amyrin synthase. Therefore, Trp259 of beta-amyrin synthase was identified to be the residue responsible for beta-amyrin formation presumably through stabilization of the cation intermediate, while lack of this effect by Leu residue may terminate the reaction at lupenyl cation stage. In further mutation studies, the residue (MWCYCR in PNY and MLCYCR in OEW) conserved in all of the OEWs producing pentacyclic triterpenes was mutated into His which is found in all of those producing tetracyclic carbon skeletons to investigate the role of this Tyr261 of PNY. PNY Y261H mutant produced dammara-18,21-dien-3 beta-ol (as a 3:5 mixture of E/Z isomer at Delta 18) together with a minor amount of dammara-18(28),21-dien-3 beta-ol, demonstrating that Tyr261 of beta-amyrin synthase plays an important role in producing pentacyclic triterpenes probably by stabilizing one of the cation intermediates generated after dammaradiene cyclization.

22/AB/3 (Item 2 from file: 34)

DIALOG(R)File 34:(c) 2001 Dialog Corporation. All rts. reserv.

Abstract: Preparative HPLC was used to separate sterols and triterpene alcohols from the unsaponifiable matters in plant oils from Camellia weiningensis L., Passiflora fulcea L. and Microula sikkimensis. The isolated sterols and triterpene alcohols were acetylated and further

purified by AgNO₃ impregnated silica gel preparative thin layer chromatography (TLC). The isolated acetyl derivatives of sterols and triterpene alcohols were identified by melting point, specific rotation, infrared and mass spectrometry. The sterols were brassicasterol, campesterol, stigmasterol, beta-sitosterol and Delta(5)-avenasterol, Delta(7)-avenasterol, Delta(7)-stigmastenol and alpha-spinasterol. The triterpene alcohols were cycloartanol, cycloartenol, 2-methylcycloartanol, cyclobranol, dammaradienol, tirucalla-7,24-dienol, beta-amyrin, germanicol, Psi-4-taraxasterol and beta-amyrin.

?

DIALINDEX(R)

(c) 2001 The Dialog Corporation plc

*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
?sf allmedph

You have 214 files in your file list.

(To see banners, use SHOW FILES command)

?s butyrospermum(w)parkii

Your SELECT statement is:

s butyrospermum(w)parkii

Items	File
18	5: MEDLINE 1969-2001/Jul W2
3	6: MEDLINE 1969-2001/Jul W2
13	10: AGRI 1969-2001/Jul W2
6	14: GALE 1969-2001/Jul W2
1	20: WOOD 1969-2001/Jul W2
5	34: SCISearch (R) Cited Ref Sci 1990-2001/Jul W2
2	40: ENVI 1975-2001/May
1	42: ENVI 1975-2001/Jul
38	51: EMBASE 1975-2001/Jul
16	51: EMBASE 1975-2001/Sep W2
2	51: EMBASE 1975-2001/Jul 11
3	69: EMBASE 1975-2001/Jul 11
2	68: ENV 1975-2001/Jul
3	71: ELSEV 1975-2001/Jul W2
4	73: EMBASE 1975-2001/Jul W2
2	74: EMBASE 1975-2001/Jul
1	75: EMBASE 1975-2001/Jul W3
1	76: EMBASE 1975-2001/Jul W3
1	77: EMBASE 1975-2001/Jul W3
1	78: EMBASE 1975-2001/Jul W3
1	79: EMBASE 1975-2001/Jul W3
1	80: EMBASE 1975-2001/Jul W3
1	81: EMBASE 1975-2001/Jul W3
1	82: EMBASE 1975-2001/Jul W3
1	83: EMBASE 1975-2001/Jul W3
1	84: EMBASE 1975-2001/Jul W3
1	85: EMBASE 1975-2001/Jul W3
1	86: EMBASE 1975-2001/Jul W3
1	87: EMBASE 1975-2001/Jul W3
1	88: EMBASE 1975-2001/Jul W3
1	89: EMBASE 1975-2001/Jul W3
1	90: EMBASE 1975-2001/Jul W3
1	91: EMBASE 1975-2001/Jul W3
1	92: EMBASE 1975-2001/Jul W3
1	93: EMBASE 1975-2001/Jul W3
1	94: EMBASE 1975-2001/Jul W3
1	95: EMBASE 1975-2001/Jul W3
1	96: EMBASE 1975-2001/Jul W3
1	97: EMBASE 1975-2001/Jul W3
1	98: EMBASE 1975-2001/Jul W3
1	99: EMBASE 1975-2001/Jul W3
1	100: EMBASE 1975-2001/Jul W3
1	101: EMBASE 1975-2001/Jul W3
1	102: EMBASE 1975-2001/Jul W3
1	103: EMBASE 1975-2001/Jul W3
1	104: EMBASE 1975-2001/Jul W3
1	105: EMBASE 1975-2001/Jul W3
1	106: EMBASE 1975-2001/Jul W3
1	107: EMBASE 1975-2001/Jul W3
1	108: EMBASE 1975-2001/Jul W3
1	109: EMBASE 1975-2001/Jul W3
1	110: EMBASE 1975-2001/Jul W3
1	111: EMBASE 1975-2001/Jul W3
1	112: EMBASE 1975-2001/Jul W3
1	113: EMBASE 1975-2001/Jul W3
1	114: EMBASE 1975-2001/Jul W3
1	115: EMBASE 1975-2001/Jul W3
1	116: EMBASE 1975-2001/Jul W3
1	117: EMBASE 1975-2001/Jul W3
1	118: EMBASE 1975-2001/Jul W3
1	119: EMBASE 1975-2001/Jul W3
1	120: EMBASE 1975-2001/Jul W3
1	121: EMBASE 1975-2001/Jul W3
1	122: EMBASE 1975-2001/Jul W3
1	123: EMBASE 1975-2001/Jul W3
1	124: EMBASE 1975-2001/Jul W3
1	125: EMBASE 1975-2001/Jul W3
1	126: EMBASE 1975-2001/Jul W3
1	127: EMBASE 1975-2001/Jul W3
1	128: EMBASE 1975-2001/Jul W3
1	129: EMBASE 1975-2001/Jul W3
1	130: EMBASE 1975-2001/Jul W3
1	131: EMBASE 1975-2001/Jul W3
1	132: EMBASE 1975-2001/Jul W3
1	133: EMBASE 1975-2001/Jul W3
1	134: EMBASE 1975-2001/Jul W3
1	135: EMBASE 1975-2001/Jul W3
1	136: EMBASE 1975-2001/Jul W3
1	137: EMBASE 1975-2001/Jul W3
1	138: EMBASE 1975-2001/Jul W3
1	139: EMBASE 1975-2001/Jul W3
1	140: EMBASE 1975-2001/Jul W3
1	141: EMBASE 1975-2001/Jul W3
1	142: EMBASE 1975-2001/Jul W3
1	143: EMBASE 1975-2001/Jul W3
1	144: EMBASE 1975-2001/Jul W3
1	145: EMBASE 1975-2001/Jul W3
1	146: EMBASE 1975-2001/Jul W3
1	147: EMBASE 1975-2001/Jul W3
1	148: EMBASE 1975-2001/Jul W3
1	149: EMBASE 1975-2001/Jul W3
1	150: EMBASE 1975-2001/Jul W3
1	151: EMBASE 1975-2001/Jul W3
1	152: EMBASE 1975-2001/Jul W3
1	153: EMBASE 1975-2001/Jul W3
1	154: EMBASE 1975-2001/Jul W3
1	155: EMBASE 1975-2001/Jul W3
1	156: EMBASE 1975-2001/Jul W3
1	157: EMBASE 1975-2001/Jul W3
1	158: EMBASE 1975-2001/Jul W3
1	159: EMBASE 1975-2001/Jul W3
1	160: EMBASE 1975-2001/Jul W3
1	161: EMBASE 1975-2001/Jul W3
1	162: EMBASE 1975-2001/Jul W3
1	163: EMBASE 1975-2001/Jul W3
1	164: EMBASE 1975-2001/Jul W3
1	165: EMBASE 1975-2001/Jul W3
1	166: EMBASE 1975-2001/Jul W3
1	167: EMBASE 1975-2001/Jul W3
1	168: EMBASE 1975-2001/Jul W3
1	169: EMBASE 1975-2001/Jul W3
1	170: EMBASE 1975-2001/Jul W3
1	171: EMBASE 1975-2001/Jul W3
1	172: EMBASE 1975-2001/Jul W3
1	173: EMBASE 1975-2001/Jul W3
1	174: EMBASE 1975-2001/Jul W3
1	175: EMBASE 1975-2001/Jul W3
1	176: EMBASE 1975-2001/Jul W3
1	177: EMBASE 1975-2001/Jul W3
1	178: EMBASE 1975-2001/Jul W3
1	179: EMBASE 1975-2001/Jul W3
1	180: EMBASE 1975-2001/Jul W3
1	181: EMBASE 1975-2001/Jul W3
1	182: EMBASE 1975-2001/Jul W3
1	183: EMBASE 1975-2001/Jul W3
1	184: EMBASE 1975-2001/Jul W3
1	185: EMBASE 1975-2001/Jul W3
1	186: EMBASE 1975-2001/Jul W3
1	187: EMBASE 1975-2001/Jul W3
1	188: EMBASE 1975-2001/Jul W3
1	189: EMBASE 1975-2001/Jul W3
1	190: EMBASE 1975-2001/Jul W3
1	191: EMBASE 1975-2001/Jul W3
1	192: EMBASE 1975-2001/Jul W3
1	193: EMBASE 1975-2001/Jul W3
1	194: EMBASE 1975-2001/Jul W3
1	195: EMBASE 1975-2001/Jul W3
1	196: EMBASE 1975-2001/Jul W3
1	197: EMBASE 1975-2001/Jul W3
1	198: EMBASE 1975-2001/Jul W3
1	199: EMBASE 1975-2001/Jul W3
1	200: EMBASE 1975-2001/Jul W3
1	201: EMBASE 1975-2001/Jul W3
1	202: EMBASE 1975-2001/Jul W3
1	203: EMBASE 1975-2001/Jul W3
1	204: EMBASE 1975-2001/Jul W3
1	205: EMBASE 1975-2001/Jul W3
1	206: EMBASE 1975-2001/Jul W3
1	207: EMBASE 1975-2001/Jul W3
1	208: EMBASE 1975-2001/Jul W3
1	209: EMBASE 1975-2001/Jul W3
1	210: EMBASE 1975-2001/Jul W3
1	211: EMBASE 1975-2001/Jul W3
1	212: EMBASE 1975-2001/Jul W3
1	213: EMBASE 1975-2001/Jul W3
1	214: EMBASE 1975-2001/Jul W3

Examined 200 files

48 files have one or more items; file list includes 214 files.

?sf hits

You have 48 files in your file list.

(To see banners, use SHOW FILES command)

```
?s butyrospermum(w)parkii a (0 1 - 0? or inflamm? or hypersensitiv? or hyper()sensitiv
?)
```

Your SELECT statement is:

s butyrospermum(w)parkii and (a) erg? or inflamm? or hypersensitiv? or hyper()sensitiv?)

Items	File
2	15: Galt Group FLOMT(R)_1990-2001/Jul 11
1	53: FOOD LINE File: Food Science & Technology 1972-2001/Jul 11
1	73: EMP-SEC 1972-2001/Jul W2
4	148: Galt Group Trade & Industry DB_1976-2001/Jul 11
1	152: GEDDING 1972-2001/Jul W3
1	156: Galt Group 1972-2001/Dec
2	148: Galt Group 1972-2001/Jul W01
10	349: Galt Group 1972-2001/UB=20010628, UT=20010621
2	351: Galt Group 1972-2001/UD, UM & UP=200138
1	374: Galt Group 1972-2001, BOPI 200127
1	376: Galt Group 1972-2001, BOPI 200127
1	377: Galt Group 1972-2001/Jul W4
1	399: Galt Group 1972-2001/UD=13503
1	500: Galt Group 1972-2001/May

14 files have one character; the list includes 48 files.

```
?save temp
```

Temp SearchSave "TD174" stored

?rf

Your last SELECT statement is

S BUTYROSPERMUM(W) PARAFFIN AND ALLERG OR INFLAMM? OR HYPERSENSITIV? OR -
HYPER()SENSITIV?)

Ref	Items	File
N1	10	348: Datasheet 1983-2001/UB=20010628, UT=20010621
N2	4	148: Semiconductor & Industry DB 1976-2001/Jul 11
N3	2	16: GMM 1990-2001/Jul 11
N4	2	348: EUROPEAN PATENTS 1978-2001/Jul W01
N5	2	351: Database 1983-2001/UD,UM &UP=200138
N6	1	51: Field Notes and Science & Technology_1972-2001/J
N7	1	73: Database 1971/31 W2
N8	1	155: Database 1960-2001/Jul W3
N9	1	156: Database 1950-2000/Dec
N10	1	371: Field Notes 1961-2001/BOPI 200127

14 files have one or more items. The list includes 48 files.

- Enter P or U, Gf Org

?b hits

12jul01 14:27:11 ... 0533.2

\$4.33 47 -1 100% 1991

\$4.33 Estimated cost.

\$0.45 TYMNET

\$4.78 Estimated c

\$4.82 Estimated Total Cost of \$1.63 DialUnits

SYSTEM:OS - DIALOG JMS etc

File 16:Gale Group; H.L.M.T.(F 99-1-01/Jul 11

(c) 2001 The Nature Group

File 53:FOODLINE(R). Food Science & Technology 1972-2001/Jul 11

(c) 2001 LFRA
 File 73:EMBASE 1974-2001/Jul W2
 (c) 2001 Elsevier Science B.V.
***File 73: For information about Explode feature please see Help News73.**
 File 148:Gale Group Trade & Industry DB 1976-2001/Jul 11
 (c)2001 The Gale Group
 File 155:MEDLINE(R) 1966-2001/Jul W3
 (c) format only 2001 DI. 39 Corporation
***File 155: This file has been reprocessed. Accession numbers have changed.**
 Please see Help News155 for details.
 File 156:Toxline(R) 1966-2001/Jul W3
 (c) format only 2001 DI. 39 Corporation
***File 156: This file is a new release. For toxicology search strategy and changes see Help News156.**
 File 348:EUROPEAN PATENT ABSTRACTS 1976-2001/Jul W01
 (c) 2001 European Patent Office
 File 349:PCT Fulltext 1976-2001/Jul W010628, UT=20010621
 (c) 2001 WIPO/Microsoft
 File 351:Derwent WPI 1966-2001/Jul W010628, UT=20010621
 (c) 2001 Derwent Information
***File 351: Price changes and updates. Please see HELP RATES 351.**
 72 Updates in 2001. Please see HELP RATES 351 for details.
 File 371:French Patent Abstracts 1976-2001/Jul W010628, UT=20010621
 (c) 2001 INPI. All rights reserved.
 File 376:Derwent Drug File 1966-2001/Jul W010628, UT=20010621
 (c) 1995 Derwent Information
 File 377:Derwent Drug File 1966-2001/Jul W010628, UT=20010621
 (c) 2001 Derwent Information
 File 399:CA SEARCH(R) 1966-2001/Jul W010628, UT=20010621
 (c) 2001 AMER. CHEM. SOC. (ACS)
***File 399: Use is subject to the ACS user/customer agreement.**
 RANK charge added; see HELP RATES 399 for details.
 File 553:Wilson Bus. Abstracts 1966-2001/May
 (c) 2001 The HW Wilson Co.

Set Items D
 --- -----

?exs
 Executing TD174
 Highlight option is not available for file(s): 399
 HIGHLIGHT set on as **
 KWIC is set to 50.
 KWIC option is not available for file(s): 399
 178 BUT (RANK) 178
 102 RANK 102
 83 RANK 83
 364040 ALLERG 364040
 684288 INFLAMM 684288
 203358 HYPERSENSITIV 203358
 40694 HYPER 40694
 1953555 SENSITIVE 1953555
 638 HYPER 638
 S1 29 ALLERG (ALLERG? OR INFLAMM? OR
 HYPER? OR SENSITIVE?)
 ?rd
 >>>Duplicate detection for file 348.
 >>>Duplicate detection for file 349.
 >>>Duplicate detection for file 351.
 >>>Duplicate detection for file 371.
 >>>Records from unprocessed files will be retained in the RD set.
 ...completed examination of file(s): 399
 S2 25 RD (ALLERG? OR INFLAMM? OR
 ?t s2/6,k/all
 >>>KWIC option is not available for file(s): 399
 2/6,K/1 (Item 1 from file: 16)

... 6), which in turn can be further elongated and desaturated to docosapentaenoic acid (C22:5n-6). The cyclooxygenase derivatives of C20:3n-6 are less *inflammatory* as a rule, than those derived from AA. This is one of the reasons that LA is commonly endowed with antiinflammatory properties. This conversion of...oil is used in cosmetics as an occlusive and bodying agent in creams and gels.

Shea butter, obtained from the fruit of the karite tree, *Butyrospermum* *parkii*, contains a high level of oleic acid, and it could be classified as a mono-unsaturated triglyceride. In cosmetics, it is widely used as an...choline. The acyl group in the 2 position is subject to enzymatic hydrolysis by phospholipase [A.sub.2] which, in body membranes, commonly releases an...unsaturated fatty acid. The remaining monoacyl derivative...cithin.

The major...stipid is crushed dried soybeans, extracted (with...).

2/6,K/7 (Item 3 from file...)
DIALOG(R)File 148:(c)2001...rts. reserv.

06787106 SUPPLIER NUMBER: 0009 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Waxing natural. (evaluation...)

Nov, 1993

WORD COUNT: 1787 LINE COUNT: 0135

... skin emollient and...time providing a protective barrier. It can be used universally across...and lipsticks.

The debate continues on the *allergy* of lanolin, with most of the evidence pointing to...a problem. Dr Ian Steel puts forward an excellent defence...

...the old day, when records had to revolve at 78rpm, it was a fundamental constituent of their composition.

Recent Waxes

Recent waxes include...Butyrospermum* *parkii*), mango butter (Mangifera indica),...sheenoptera), babassu palm fat (Orbygnia martiana) and...guineensis).

West Afri...

2/6,K/8 (Item 1 from file...)
DIALOG(R)File 348:(c)2001...Office. All rts. reserv.

01288417

Cosmetic and dermatological...in the form of O/W-macro or -micro-emulsions...

Kosmetische und dermatologische...Schutzformulierungen in Form von O/W-Makroemulsionen oder...mit einem Gehalt an Sheabutter...

Filtres solaires...dermatologiques sous forme de macro- ou micro-emulsions de type...ant du beurre de karite

LANGUAGE (Publication, edition): German; German; German

FULLTEXT AVAILABILITY

Available Text Language: ...unt.

CLAIMS A (German)

SPEC F

Total word count: ...6

Total word count: ...6

Total word count: ...6

...SPECIFICATION Verlust von...Stoffen (z.B. Wasser, natuerliche Fette, Elektrolyte) gesteckt...wiederhergestellt wird.

Wird diese Funktion...zu verstärkter Resorption toxischer oder...zum Befall von Mikroorganismen und als Folge zu...Hautreaktionen kommen.

Ziel der Hautpflege...durch tagliche Waschen

verursachten Fett- und Wasserverlust der Haut auszugleichen. Dies ist gerade dann wichtig, wenn...

...Substanzen, also Emulgatoren, nötig. Ansich ist die Verwendung der üblichen kosmetischen Emulgatoren völlig unbedenklich. Dennoch können Emulgatoren, wie letztlich jede chemische Substanz, im Einzelfalle *allergische* oder auf Überempfindlichkeit des Anwenders beruhende Reaktionen hervorrufen. So ist bekannt, dass bei manchen besonders empfindlichen Personen bestimmte Lichtdermatosen durch gewisse Emulgatoren und gleichzeitige Einwirkung...Menge an Sheabutter, den Nachteilen des Standes der Technik abhelfen.

Sheabutter (auch: Sheafett, Karitefett oder Caritefett, Galambutter) ist ein natürliches Fett, das aus dem Samen der Pflanze *Butyrospermum* *parkii*, dem afrikanischen Sheabaum, gewonnen wird und in kommerziellen Mengen vornehmlich in der Kosmetik enthalten ist. Sheafett enthält 89 bis 98 Gew.-% Triglyceride, 1 bis 10 Gew.-% freie Fettsäuren sowie einen...

2/6,K/9 (Item 2 from 34)

DIALOG(R) File 348: (c) 1990 by Dialog. All rights reserved.

01245757

Oil-in-water preparations for cosmetic or dermatologic use

Kosmetische oder dermatologische Zubereitungen von Typ Öl-in-Wasser

Preparations cosmétiques ou dermatologiques du type huile dans l'eau

LANGUAGE (Publication, Procedure, Application): German; German; German

FULLTEXT AVAILABILITY:

Available Text Language Updated Word Count

CLAIMS A German 1990 31

SPEC A German 1990 31

Total word count - document A 31

Total word count - document A 31

Total word count - document A + B 9220

...SPECIFICATION Mengen an und von mehreren Emulgatoren erforderlich sind (z. B. 3 Gew.-% von mehreren Emulgatoren - wie letztendlich jede chemische Substanz - im Einzelfalle *allergische* oder auf Überempfindlichkeit des Anwenders beruhende Reaktionen hervorrufen können (obwohl diese Substanzen in der Kosmetik üblicherweise in geringen Mengen enthalten sind). Ein natürliches Fett, das aus dem Samen der Pflanze *Butyrospermum* *parkii* (CAS-Nr. 68920-03-6) gewonnen wird, ist auch Karitefett oder Sheafett. Sheabutter ist das Fett der Samen der Pflanze *Butyrospermum* *parkii* (Familie der Sapotaceae) und enthält zu etwa 34 bis 45 Gew.-% aus festen Fettsäuren (vornehmlich Stearinsäure) und zu etwa 50 bis 60 Gew.-% aus flüssigen Fettsäuren (vornehmlich Ölsäure) bestehend...

2/6,K/10 (Item 10 from 34)

DIALOG(R) File 349: (c) 1990 by Dialog. All rights reserved.

00774939

LYSINE OXIDASE LINKAGE OF LYSINE

LIAISON D'AGENTS A LYSINE

Publication Language: English

Filing Language: English

Fulltext Available: Yes

Detailed Description

Claims

Fulltext Word Count: 1188

Publication Year: 2001

Fulltext Availability

Detailed Description

Detailed Description

... oleifera; bre. bon. la; bre. bon. la; butyl acetyl ricinoleate; butyl isostearate; butyl myristate; butyl oleate; butyl stearate; butylene

glycol dicaprylate/dicaprate; butylene glycol montanate; butyloctyl beeswax; butyloctyl oleate; *butyrospermum* *parkii*; butyroyl trihexyl citrate; butyrum; buxus chinensis; C 10- 18 triglycerides; C I 1- 15 pareth- 12 stearate; C I 1- 15 pareth-3 oleate; C...Rutin; Saffloweramidopropyl Ethyldimonium Ethosulfate; Salicylic Acid; Selenium Sulfide; Sericin; Serine; Serum Albumin; Serum Protein; Sesame (Sesamum Indicum) Oil Unsaponifiables; Sesamidopropylamine Oxide; Sesamidopropyl Betaine; Shea Butter (*Eulyrospermum* *Parkii*) Unsaponifiables; Shellac Wax; Silicone Quaternium-1; Silicone Quaternium-2; Silicone Quaternium-3; Silicone Quaternium-4; Silicone Quaternium-5; Silicone Quaternium-6; Silicone Quaternium-7; Silicone...As mentioned above, the agent may be a pharmaceutical agent.

Examples of categories of pharmaceutical agents include: analgesic; amino acid; antagonist; anti-asthmatic; anti-allergic; anti-asthmatic; antibacterial; anticholinergic; antidiabetic; antihypertensive; antitumor agent; antihistamine; anti-infective; anti-infective, topical; anti-*inflammatory*; antikeratinizing agent; antimicrobial; antimycotic; antineoplastic; antineutropenic; antipruritic; antipruritic; antiseborrheic; carbonic anhydrase inhibitor; cholinergic; cholinergic agonist; diagnostic; diuretic; fluorescent agent; glucocorticoid; hair growth stimulant; histamine...Nitromersol; Octenidine Hydrochloride; Oxychlorosene; Oxychlorosene Sodium; Parachlorophenol, Camphorated; Potassium Permanganate; Povidone-Iodine; Sepazonium Chloride; Silver Nitrate; Sulfadiazine, Silver; Symclosene; Thimerfonate Sodium; Thimerosal; Troclosesene Potassium. Anti-*inflammatory*: Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase.

2/6,K/11 (Item 1 from List 1)
DIALOG(R) File 349: (c) 2003, All rights reserved.

00774894

LINKAGE OF AGENTS TO TISSUE

LIAISON D'AGENTS AVEC LE TISSU

Publication Language: English

Filing Language: English

Fulltext Available

Detailed Description

Claims

Fulltext Word Count: 1,000

Publication Year: 2000

Fulltext Available

Detailed Description

Detailed Description

... oleifera; brevis; butyl acetate; butyl acetate ricinoleate; butyl isostearate; butyl myristate; butyl stearate; butylene glycol dicaprylate/dicaprate; butylene glycol montanate; butyloctyl beeswax; butyloctyl oleate; *butyrospermum* *parkii*; butyroyl trihexyl citrate; butyrum; C 10- 18 triglycerides; C I 1- 15 pareth- 12 stearate; C I 1- 15 pareth-3 oleate; C...mentioned above, the agent may be a pharmaceutical agent. Examples of categories of pharmaceutical agents include: analgesic; amino acid; antagonist; anti-asthmatic; anti-allergic; anti-asthmatic; antibacterial; anticholinergic; antidiabetic; antihypertensive; antitumor agent; antihistamine; anti-infective; anti-infective, topical; anti-*inflammatory*; antikeratinizing agent; antimicrobial; antimycotic; antineoplastic; antineutropenic; antipruritic; antipruritic; antiseborrheic; carbonic anhydrase inhibitor; cholinergic; cholinergic agonist; diagnostic; diuretic; fluorescent agent; glucocorticoid; hair growth stimulant; histamine...Octenidine Hydrochloride; Oxychlorosene; Oxychlorosene Sodium; Parachlorophenol, Camphorated; Potassium Permanganate; Povidone-Iodine; Sepazonium Chloride; Silver Nitrate; Sulfadiazine, Silver; Symclosene; Thimerfonate Sodium; Thimerosal; Troclosesene Potassium.

Anti-*inflammatory*: Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anitrolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole;

2/6,K/12 (Item 3 from file 34)
DIALOG(R)File 349:(c)2001 All rts. reserv.

00773330

TREATMENT AND COMPOSITION FOR THE ANTI-AGING BENEFITS BY CORNEUM
PROTEASE ACTIVATION

TRAITEMENT ET COMPOSITION PERMETTANT DES EFFETS ANTI-VIEILLISSEMENT PAR
ACTIVATION DES PROTEASES DE LA CORNEE

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 9431

Publication Year: 2001

Fulltext Availability:

Detailed Description

Detailed Description

... as "epidermal cell" ... samples of injuries which can increase epidermal ... abrasion, chemical damage, pH extremes, excessive ... of allergic* or non-*allergic* contact irritation. ... severe, the increased replication will result in a "thick" epidermis and a thickened, poorly functioning ... rose oil, safflower (carthamus tinctorius) oil, ... salicylic acid, sandalwood (santalum ... protein, sesame (sesamum indicum) oil, ... silk powder, sodium chondroitin sulfate, ... sodium lactate, sodium palmitate, ... glutamate, sodium stearate, soluble collagen, ... rate, etc.), vitamins (i.e. A, C, E, K, etc.), ... calcium, selenium, etc.), anti-irritants (e.g. ... anti-*inflammatories*, etc.), antimicrobial agents (e.g. ... osan, etc.), botanical extracts (e.g. aloe vera, chamomile, ... ginkgo bibloba, ginseng, rosemary, etc.), ... ts...

2/6,K/13 (Item 4 from file 34)
DIALOG(R)File 349:(c)2001 All rts. reserv.

00771732

COMPOSITION CONTAINING ... TYROSPERMUM* *PARKII* AND THE USE AS
MEDICAMENT OR DIETARY

COMPOSITION CONTENANT ... DE BUTYROSPERMUM* *PARKII* ET
UTILISATION EN TANT QUE ... SUPPLEMENT ALIMENTAIRE

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 1094

Publication Year: 2001

COMPOSITION CONTAINING ... TYROSPERMUM* *PARKII* AND THE USE AS
MEDICAMENT OR DIETARY SUPPLEMENT

COMPOSITION CONTENANT ... EXTRAITS DE *BUTYROSPERMUM* *PARKII* ET
UTILISATION EN TANT QUE ... SUPPLEMENT ALIMENTAIRE

Fulltext Availability:

Detailed Description

Claims

English Abstract

The present invention relates to a composition comprising an extract or a concentrate of **Butyrospermum* *parkii** as a dietary supplement or a pharmaceutical composition and to the use of such compositions for the preparation of a medicament or dietary supplement for the suppression of **hypersensitivity** and/or **inflammatory** reaction. The composition may optionally be formulated with a pharmaceutically acceptable carrier for systemic or topical administration. More specifically, the invention relates to a dietary supplement or pharmaceutical composition comprising an extract or concentrate of **Butyrospermum* *parkii**, wherein said extract or concentrate contains Butyrospermum-triterpenes and optionally the sterols *stigmasterol*, *avenasterol*, 24-methyl-cholest-7-enol, *karitosterol A*, *karitesterol B* and α -...

French Abstract

La presente invention concerne une composition contenant un extrait ou un concentré de **Butyrospermum* *parkii** en tant que supplément alimentaire ou une composition pharmaceutique ainsi que l'utilisation de ces compositions dans la préparation d'un médicament ou d'un supplément alimentaire destiné à la suppression de la réaction d'hypersensibilité et/ou **inflammatoire**. La composition peut être formulée facultativement avec un excipient acceptable pour une composition pharmaceutique destinée à une administration systémique ou locale. Plus spécifiquement, l'invention concerne un supplément ou une composition pharmaceutique contenant un extrait ou un concentré de **Butyrospermum* *Parkii**, dans lequel ledit extrait ou concentré contient des Butyrospermum-Triterpènes et facultativement les stéroïdes *stigmasterol*, *avenasterol*, 24-méthyl-cholest-7-enol, *karitosterol A*, *karitesterol B*...

Detailed Description

COMPOSITION CONTAINING **BUTYROSPERMUM* *PARKII**
AND THE USE OF SUCH COMPOSITIONS

FIELD OF THE INVENTION

The present invention relates to a dietary supplement or a pharmaceutical composition for systemic or topical administration comprising an extract or a concentrate of **Butyrospermum* *parkii** optionally formulated with a pharmaceutically acceptable carrier for systemic or topical administration. More specifically, the invention relates to a dietary supplement or a pharmaceutical composition comprising an extract or a concentrate of **Butyrospermum* *parkii** wherein said extract or concentrate contains butyrospermol, lupeol, parkeol, germanicol, stigmasterol, α -methylene dammarenol, (x)-amyrin and P-amyrin and optionally...

...B and a spinasterol. The use of such compositions for the preparation of a medicament or dietary supplement for the suppression of **hypersensitivity** and/or **inflammatory** reaction.

BACKGROUND OF THE INVENTION

Hypersensitivity is a term used to describe a type of reactivity in which the body reacts with an exaggerated response to a substance (antigen). **Hypersensitivity** may be caused by exogenous or endogenous antigens.

Hypersensitivity is associated with a large number of diseases. Among these, **allergic** and **autoimmune** diseases are of great importance. A classification of these diseases is given in the textbook Clinical Medicine, 3rd edition, M. : "Clinical Medicine", 3rd edition, p. 147 (1978, 1979, 1980, 1981, London).

Type I **hypersensitivity** reactions (IgE mediated **allergic** reactions) are caused by **allergens** (so-called exogenous antigens), e.g. pollen, house dust, animal dander, foods, etc. Allergic diseases in which type I reactions play a significant role include asthma, eczema (atopic

dermatitis), urticaria, allergic rhinitis and anaphylaxis.

Type I **hypersensitivity** reactions are caused by cell surface or tissue bound antibodies (IgG and IgM) and play a significant role in the pathogenesis of myasthenia gravis, Good pasture's syndrome and Addisonian pernicious anaemia.

Type III **hypersensitivity** reactions (immune complex) are caused by autoantigens or exogenous antigens, such as certain bacteria, fungi and parasites. Diseases in which type III **hypersensitivity** reactions play a significant role include, rheumatoid arthritis, hematosus, rheumatoid arthritis and glomerulonephritis.

Type IV **hypersensitivity** reactions (delayed) are caused by cell or tissue bound antigen.

This type of **hypersensitivity** reactions play a significant role in a number of conditions, e.g. graft versus host disease, leprosy, contact dermatitis and reactions due to insect bites.

A number of drug classes are available for the treatment of **hypersensitivity** reactions.

Among these the corticosteroids are some of the most widely used drugs. Corticosteroids primarily exert their pharmacological action by non-selectively inhibiting the synthesis and proliferation of different classes of immune cells resulting in suppression of **hypersensitivity** reactions. Unfortunately, the corticosteroids are associated with a number of serious side effects, e.g. immuno-suppression, osteoporosis and skin atrophy.

The African tree...such...should be maximum 1 % (w/w).

FIR 2770400 (WO 99/00000) discloses a composition of dermopharmaceutical compositions comprising an extract of **Butyrospermum* parkii*. The inventor has isolated the chemical components of the flowers, but to the inventor's best knowledge the flowers do not contain any substantial amounts of these components.

...the patent butyrospermum...extract from *Butyrospermumparkii*.

To the inventor's best knowledge the pharmaceutical compositions according to the invention comprise extracts or concentrates of **Butyrospermum* parkii* as described in further detail in the following have never been disclosed in the literature.

SUMMARY OF THE INVENTION

It has been found by the present inventor that a composition comprising an extract or a concentrate of **Butyrospermum* parkii*, said extract or concentrate comprising a butyrospermum-triterpene fraction, said fraction being selected from the group consisting of butyrospermum triterpenes and sterols.

...triterpenes and sterols...in the form of free alcohols or esters thereof, especially in the form of butyric acid or fatty acid esters significantly suppress **hypersensitivity** reactions when used in systemic administration. The composition, said extract or concentrate comprises a pharmaceutically acceptable carrier for systemic administration.

Furthermore, it has been found by the present inventor that a pharmaceutical composition comprising at least 5% Butyrospermum-triterpenes and sterols is a pharmaceutically acceptable carrier when applied topically significantly inhibits **inflammation** or **hypersensitivity** of the mucous membranes. This is surprising because such effects are not obtainable with the lower levels of Butyrospermum triterpenes and sterols mentioned above, the

pharmaceutical compositions and dietary supplements according to the invention can be employed for the following therapeutic applications: Immunomodulation.

Treatment or prevention of *hypersensitivity* diseases.

Treatment or prevention of *inflammation* or *hypersensitivity* of the skin.

Treatment or prevention of *inflammation* or *hypersensitivity* of mucous membranes.

Treatment or prevention of *allergic* reactions and conditions.

Treatment or prevention of *pain*.

Alleviation of pain.

Accordingly, the present invention provides a dietary supplement or a pharmaceutical composition comprising:

1. an extract or a concentrate of *Butyrospermum parkii*, said extract or concentrate comprising at least 5% of a Butyrospermum-triterpene fraction, said triterpenes being selected from the group consisting of butyrospermol, lupeol...

...skin or mucous membrane.

Furthermore, the present invention provides the use of a composition for systemic administration comprising an extract or a concentrate of *Butyrospermum parkii* or a pharmaceutically acceptable carrier for the preparation of a medicament for immunomodulation in a mammal, for the suppression of *hypersensitivity* reactions in a mammal, such as IgE mediated *allergic* reactions or autoimmune reactions in a mammal, and for the alleviation of *pain*.

Thus, according to the invention, a composition comprising an extract or a concentrate of *Butyrospermum parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration is used in a method for the treatment or prevention of a *hypersensitivity* reaction in a mammal, said method comprising administering said composition to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of *hypersensitivity* diseases in a mammal.

Also, according to the invention, a composition comprising an extract or a concentrate of *Butyrospermum parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration is used in a method for the treatment or prevention of *pain* in a mammal.

Further, according to the invention, a composition comprising an extract or a concentrate of *Butyrospermum parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration is used in a method for the treatment or prevention of an *allergic* reaction or condition in a mammal, said method comprising administering said composition to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of IgE mediated *allergic* reactions and conditions in a mammal.

Also, according to the invention, a composition comprising an extract or a concentrate of *Butyrospermum parkii* as described above for systemic administration and a pharmaceutically acceptable carrier for systemic administration is used in a method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membrane in a mammal.

systemic administration can be used in a method for the alleviation of...

...comprising at least 5% Butyrospermum-triterpenes and optionally a pharmaceutically acceptable carrier can be used in a method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes in a mammal, said method comprising administering said composition topically to said mammal; and the invention comprises the use of said composition for the preparation of a medicament for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes in a mammal.

Also, according to the invention a pharmaceutical composition comprising at least 5% Butyrospermum-triterpenes and optionally...

...INVENTION

It has been found by the present inventor that a dietary supplement or a pharmaceutical composition comprising:

1. an extract or a concentrate of Butyrospermum* *parkii*, said extract or concentrate comprising at least 5% of a Butyrospermum-triterpene fraction, said triterpenes being selected from the group consisting of butyrospermol, lupeol, stanoic acid or fatty acid esters; and optionally
3. a pharmaceutically acceptable carrier said carrier being suitable for either systemic or topical administration, significantly suppresses *inflammation* or *hypersensitivity* reactions.

Said pharmaceutical composition may be adapted for either systemic administration or for topical administration to the skin or mucous membrane.

In example 1 the anti-inflammatory effect of a composition according to the invention was tested in a well established model of *hypersensitivity* (Draize test). In this experiment the composition of the invention showed a significant effect (at 50 mg/kg) comparable to that of indomethacin.

...Thus, the therapeutic index of a composition of the invention is far superior to that of cyclophosphamide.

When applied topically the pharmaceutical composition inhibits *inflammation* or *hypersensitivity* of the skin or mucous membranes.

In example 2 the topical anti-inflammatory* effects of different compositions according to the invention are compared to an ordinary composition (control) consisting of sea butter corresponding to 2% Butyrospermum-triterpenes. The compositions according to the invention containing 10-30% butyrospermum-triterpenes dose-dependently inhibit the *inflammation* of the skin. The control has no anti-inflammatory effect. These results show that such effects are not obtainable with the other triterpenes of Butyrospermum-triterpenes that, through the action of the triterpenes...

...far been used in food, pharmaceutical or cosmetic products.

The compositions of the invention, either topical or systemic administration, possess a very good anti-*hypersensitivity* and anti-*inflammatory* profile, a very good safety profile. Thus, the compositions of the invention are usually non-toxic and yet very therapeutically effective. The inventor puts forward the hypothesis that the very high therapeutic index of the compositions of the invention compared to single chemical anti-*hypersensitivity* drugs is due to the more balanced nature of the compositions of the invention, giving a lower toxic load on the body of any...

...the composition

More specifically, the following additional compositions of the invention provide the following additional effects upon administration to the

living organism:

Immunomodulation.

Suppression of *hypersensitivity* reactions.

Inhibition of *inflammation* or *hypersensitivity* of the skin. This effect can be obtained in relation to any skin disease or in relation to any disease giving rise to the symptoms of the skin, such as atopic dermatitis, psoriasis, eczema, dermatitis or infectious diseases.

Inhibition of *inflammation* or *hypersensitivity* of mucous membranes. This effect can be obtained in relation to any disease related to mucous membranes or in relation to any disease giving rise to such symptoms of the mucous membranes.

Suppression of immediate allergic reactions.

Suppression of autoimmune reactions.

Reduction of pain.

Accordingly, the present invention provides a pharmaceutical composition or a dietary supplement comprising:

1) an extract or concentrate of *Butyrospermum parkii* containing at least 5% (w/w) of a triterpene fraction comprising:

- at least 2% (w/w) lupanol
 - at least 2% (w/w) lupenol
- ...the fruit. Furthermore, the concentrate of the invention may be derived from the oil of the fruit (nut), leaves, stem, bark or root. Preferably the concentrate of...

a pharmaceutical composition or dietary supplement comprising:

i) an extract or concentrate of *Butyrospermum parkii* containing at least 5% (w/w) of a saponin fraction comprising:

- 10-40% (w/w) a-sapogenin
 - optionally 1-30% may be in the form of free alcohol
- ...the fruit. Furthermore, the concentrate of the invention may be derived from the oil of the fruit (nut), leaves, stem, bark or root. Preferably the concentrate of...

The extract or concentrate of *Butyrospermum parkii* may be derived from any part of the plant, namely the fruit (nut), leaves, stem, bark or root. Preferably the concentrate of...

...the fruit. Furthermore, the concentrate of the invention may be derived from the oil of the fruit (nut), leaves, stem, bark or root. Preferably the concentrate of...

Extracts or concentrates according to the invention can i.a. be obtained by extraction or distillation (e.g. hydro, steam or vacuum distillation) of fresh or dried *Butyrospermum parkii* or parts thereof, preferably the nut. Extraction may be performed with a number of different organic solvents. The extracts may be obtained hot or cold...

...of extraction...

By changing the composition of the solvent, the extraction can be made more selective for certain constituents of *Butyrospermum parkii* thus enhancing or reducing the content thereof in the finished extract or concentrate.

After extraction, column chromatography or any type of distillation, can be employed to remove or separate any constituent of the extract. Hereby, the composition of the *Butyrospermum parkii* can be avoided or concentrated in the finished extract. Thus the content of any component can be standardized to obtain a composition according to the...

...The above mentioned pharmacological actions provide part of the rationale for the following therapeutic applications of a composition comprising an extract or concentrate of *Butyrospermum parkii* as described above and, optionally, a pharmaceutically acceptable carrier for systemic administration:

A method for the treatment or prevention of **hypersensitivity** disease or **inflammation** characterised by the administration of the above mentioned compositions. The therapeutic action may be relevant to all known diseases associated with **hypersensitivity** reactions or **inflammation**. Autoimmune disorders and **allergic** conditions are described below in more detail. Besides these therapeutic areas, the action of the above mentioned compositions is relevant to all known conditions characterised by **hypersensitivity** reaction, and the following conditions are not limited to this: infections (viral, bacterial, fungal, parasitic, etc.), cold and flu, contact dermatitis, insect bites, allergic vasculitis, postoperative reactions, trans plantation rejection (graft-versus-host disease), etc. A method for the treatment or prevention of autoimmune disorders characterised by the administration mentioned compositions. The applicant puts forward the hypothesis that the therapeutic action is due to the immuno modulating and suppressing effect on **hypersensitivity** reactions of the above mentioned composition. The therapeutic action may be relevant to all known autoimmune disorders and the following examples are not limiting with respect to this: Autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, **Inflammatory** myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Cushing's syndrome, Autoimmune glomerulonephritis, Progressive systemic sclerosis, Sjogren's syndrome, Sjogren's Disease, Lupus Erythematosus.

...Rheumatoid Arthritis, Gout, Osteoarthritis, Medial Connective Tissue Disease, Psoriasis, IgE mediated, Dermatitis Herpetiformis, etc. A method for the treatment or prevention of an IgE mediated **allergic** reaction or condition characterised by the administration of the above mentioned composition. The applicant puts forward the hypothesis that the therapeutic action is due to the suppressing effect on **hypersensitivity** reactions of the above mentioned compositions. The therapeutic action may be relevant to all known IgE mediated **allergic** reactions and conditions and the following examples are not limiting with respect to this: asthma, urticaria (e.g. atopic dermatitis), urticaria, **allergic** rhinitis, etc. A method for the treatment or prevention of any condition characterised by pain characterised by the administration of the above mentioned compositions. The applicant puts forward the hypothesis that the therapeutic action is related to immunomodulation. The therapeutic action is related to **hypersensitivity** reactions.

Accordingly, the compositions of the invention are suitable for the treatment or prevention of diseases caused by **inflammation** of various tissues, e.g. **inflammation** of the prostate, in particular prostatitis.

"Prostatitis" is defined as **inflammatory** conditions affecting the prostate, including acute and chronic infections with specific bacteria and, more commonly, **inflammation** with signs and symptoms of prostatic **inflammation**. The causative **inflammatory** organism can be detected. Accordingly, the compositions of the invention may also be employed for the management of benign prostatic hyperplasia.

...for topical use may be employed with the addition of an extract of *Calendula officinalis*. In example 3, where the topical anti **inflammatory** composition is a pharmaceutical composition containing 0.1% *Calendula officinalis* extract and 20% *Butyrospermum triterpene* extract, the composition is superior to a topical pharmaceutical composition containing the same therapeutic applications of a pharmaceutical composition for topical application according to the invention as described above.

A method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes of a mammal, characterised by administering a pharmaceutical composition according to the invention to said mammal. The therapeutic action may be relevant to all known diseases associated with *hypersensitivity* reactions or *inflammation*, including autoimmune disorders and IgE mediated *allergic* conditions. The action of the above mentioned pharmaceutical compositions according to the invention is relevant to all known conditions and diseases associated with *hypersensitivity* reaction, and the following examples. The following examples are given with respect to this:- infections (viral, bacterial, fungal, parasitic, etc.), cold and flu, contact dermatitis, allergic rhinitis, conjunctivitis, postoperative reactions, transplant rejection (graft-versus-host disease), asthma, eczema (eczema), allergic rhinitis, allergic rhinitis, anaphylaxis, allergic rhinitis, allergic rhinitis, Primary sclerosing cholangitis, Autoimmune hemolytic anemia, Grave's disease, Myasthenia gravis, Type 1 Diabetes Mellitus, *Inflammatory* myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn's Disease, Ulcerative Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary biliary cirrhosis. For the preparation of a pharmaceutically active composition as described above for systemic administration characterised by obtaining an extract or a concentrate of *Butyrospermum* *parkii* seed extract or concentrate comprising at least one triterpene alcohol selected from the group consisting of butyrospermol, lupeol, parkiol, stigmastanol, cammaradienol, 24-methylene dammaranol administered.

EXAMPLES

Example 1

Summary of the study

BPC, a concentrate of Butyrospermum parkii according to the invention, was evaluated for its anti-inflammatory activity in BALB/c mouse arthritis induced by adjuvant arthritis (AA) and antibody (mAb) and lipopolysaccharide. The concentrate was administered orally once daily for 3...

...14 and 17.

Test substance

A composition according to the invention was prepared by fractionation of shea butter and subsequent distillation of the obtained concentrate of *Butyrospermum* *parkii* seed extract. The applied concentrate of Butyrospermum parkii seed extract contained 26% of a Butyrospermum parkii seed extract. The composition of compositions according to the invention, the object of a known composition containing, the composition of compositions applied a way of topical anti-inflammatory activity in the mouse in inflammation in the mouse.

Methods

Four compositions according to the invention, a control composition containing shea butter and the control composition. The four pharmaceutical compositions according to the invention were prepared by the addition of Butyrospermum parkii seed extract (obtained by fractionation of shea butter) to the corresponding to a content of Butyrospermum parkii seed extract of 0.1, 0.2, 0.3, and 0.4.

The control composition was administered orally to the mice.

The assay was performed according to the method (Euro. J. Pharmacol. (1987)142:197).

Ear *inflammation* was induced by topical application of phorbol ester. Groups of five BALB/c mice were pre-treated 30 minutes before phorbol ester application and 15 minutes after.

...according to the invention containing at least 5% Butyrospermum-triterpenes, showed marked anti-inflammatory effects, while an ordinary shea butter formulation has no anti *inflammatory* effect.

Thus the study clearly demonstrates that a pharmaceutical composition according to the invention is pharmacologically far superior to an ordinary Shea Butter formulation.

Example...

...20% Butyrospermum-triterpenes and 10% Butyrospermum triterpenes and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10% extract were compared in a well established assay of topical anti-inflammatory activity, phorbol ester induced *inflammation* in the mouse.

Methods

Two compositions according to the invention and a negative control composition were prepared based on the following creme base:

Hydrogenated rapeseed...

...control composition was prepared without any further addition. The two pharmaceutical compositions according to the invention were prepared by the addition of a concentrate of Butyrospermum *parkii* (obtained by fractionation of the shea butter) according to a content of Butyrospermum-triterpenes. The further one of them was...

...1 % Calendula extract and 1 % (preparatory supercritical CO2 extraction).

The assay was performed according to Chang et al (Euro. J. Pharmacol. (1987) 142:197).

Ear *inflammation* was induced by topical application of phorbol ester. Groups of five BALB/c mice were pre-treated 30 minutes before phorbol ester application and 15 minutes after.

Test substance

A composition according to the invention was prepared by fractionation of shea butter and subsequent concentration of the obtained concentrate of *Butyrospermum* *parkii* to 11. The applied concentrate of Butyrospermum (term BPC) contained 33% of a Butyrospermum-triterpenes concentrate.

...and placebo controlled study is performed in patients suffering from atopic dermatitis to test the safety and efficacy of a concentrate of *Butyrospermum* *parkii* according to the invention.

Test substance

A composition according to the invention is prepared by fractionation of shea butter and subsequent concentration of the obtained concentrate of *Butyrospermum* *parkii* to 11. The capsules each containing 750 mg of the concentrate of Butyrospermum (term BPC) in the following study and placebo controlled phase II clinical study is performed in patients suffering from psoriasis to test the safety and efficacy of the concentrate of *Butyrospermum* *parkii* according to the invention.

A similar study in 20% patients suffering from atopic dermatitis using the same pharmaceutical composition according to the invention is under preparation.

Test substance

A composition according to the invention is prepared by fractionation of shea butter and subsequently concentrating the obtained concentrate of *Butyrospermum* *parkii* in a standard cream base containing 40% of the concentrate. The components of the cream base are:

Water, PEG-6 stearate, Glycerol, Stearic acid, PEG-32...

Claim

CLAIMS

1. A pharmaceutical composition or dietary supplement comprising:

i) an extract or concentrate of *Butyrospermum* *parkii* containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:

- at least 20% (w/w) of stigmaterol
- at least 1% (w/w) of 24-methyl-cholest-7-en-3-ol...

...fatty acid esters; and ii) optionally a pharmaceutically acceptable carrier.

2. A pharmaceutical composition or dietary supplement comprising:

i) an extract or concentrate of *Butyrospermum* *parkii* containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:

- optionally 2-30% germenol, 24-methyl-cholest-7-en-3-ol, 24-methylene-dammarenol and/or parkeol, where the sum of these components is at least 1% (w/w) of the extract or concentrate.

...ii) optionally a pharmaceutically acceptable carrier.

3. A pharmaceutical composition or dietary supplement according to claim 1 or 2, where the extract or concentrate of *Butyrospermum* *parkii* further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmaterol, avenasterol, 24-methyl-cholest-7-en-3-ol, 24-methyl-cholest-7-en-3-ol...

...preceding claims, where the Butyrospermum-triterpene fraction optionally together with the sterol fraction comprises up to 100% (w/w) of the extract or concentrate of *Butyrospermum* *parkii*.

5. A pharmaceutical composition or dietary supplement according to any of claims 3 or 4, where the extract or concentrate of the Butyrospermum-triterpene fraction and the...

...of a composition according to any of claims 1 to 9 for the preparation of a medicament or a dietary supplement for the suppression of *hypersensitivity* or *inflammation* in a mammal.

12. The use of a composition according to any of claims 1 to 9 for the preparation of a medicament or a dietary supplement for the prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes in a mammal.

13. The use according to claim 12 for the preparation of a medicament or a dietary supplement for the treatment or prevention of autoimmune disease and/or inflammatory disease in a mammal.

14. The use according to claim 12 for the preparation of a medicament or a dietary supplement for the treatment or prevention of...

...a dietary supplement for the treatment and/or prevention of prostatitis and/or benign prostatic hyperplasia.

17. A method for the treatment or prevention of *hypersensitivity* or *inflammation* in a mammal, where the method is by administering a composition according to any of claims 1 to 9 to a mammal.

18. A method for the treatment or prevention of *inflammation* or *hypersensitivity* of the skin or mucous membranes of a mammal,

characterised by administering a composition according to any of claims 1 to 9 to said mammal.

19. A method for the prevention of an autoimmune disorder and/or a chronic inflammatory disorder in a mammal, characterised by administering a mixture according to any of claims 1 to 9 to said mammal.

20. A method for the...

...A method for the preparation of a composition according to any of claims 1 to 9, characterised by obtaining an extract or a concentrate of *Butyrospermum* *parkii* or a concentrate containing at least 5% (w/w) of a Butyrospermum extract comprising:

- at least 1...
- at least 2...

...esters thereof, especially linoleic acid, acetic acid or fatty acid esters; and 24. A method according to claim 22, wherein the extract or concentrate of *Butyrospermum* *parkii* further comprises a sterol fraction comprising ... especially cinnamic acid, acetic acid or fatty acid esters.

25. A method according to claim 21 or 23, wherein said extract or concentrate of *Butyrospermum* *parkii* is further mixed with a pharmaceutically acceptable carrier.

2/6,K/14 (Item 5 from 345)

DIALOG(R) File 345 (c) 2000 International reserv.

00680915

COMPOSITIONS FOR THE SKIN OF MAMMALS CONTAINING A MIXTURE OF GREEN COFFEE EXTRACT AND BUTYROSPERMUM

COMPOSITIONS A USAGE COSMETIQUE ET MEDICALE CONTENANT UN MELANGE D'EXTRAITS DE CAFE VERD ET DE KARITE

Publication Language: French

Filing Language: French

Fulltext Available:

Detailed Description:

Claims

Fulltext Word Count: 100

Publication Year: 1996

Fulltext Availability:

Detailed Description:

Claims

English Abstract:

...plant extract of Coffea canephora<i> or <i> Coffea canephora<i> grown in the wild or obtained from the shea tree or <i> *Butyrospermum* *parkii* or its use in cosmetic or dermopharmaceutical compositions. The product resulting from said association is used in cosmetic or...

...medicine for healing... soothing effects, including treatment against... medical forms of oxygen such as, for example... skin ageing or withering, occurrence of wrinkles... protection of the hair, scalp, nail and mucous membranes.

French Abstract:

...<i> ou <i> Coffea canephora<i> ou <i> Coffea canephora<i> obtenu a partir d'extraits de karite ou <i> *Butyrospermum* *parkii*<i> ou l'association de ces deux compositions a usage cosmétique et médicamenteux. Le produit résultant de cette association est utilisé tant que...

...et la recherche d'effets apaisants cutanés, y compris contre les conséquences des effets néfastes des formes radicalaires de l'oxygène comme, par exemple, l'irritation cutanée, le vieillissement ou le dessèchement prématuré du cuir chevelu, ainsi que pour favoriser la protection des cheveux, du cuir chevelu...

Detailed Description

... dermatopharmaceutique contenant un mélange d'extraits de café vert et de beurre de karité. Les sensations douloureuses et de gêne ressenties localement lors d'épisodes d'allergie cutanée, sont dues à la désormais trilogie classique (Allergie cutanée) des signes cardinaux suivants: erythème, oedème et douleur.

Les formes radicalaires de l'oxygène...

...Okuda, 1987, p. 53-529

Le second mécanisme réside dans l'activation de différents types de cellules qui sécrètent des molécules pro-inflammatoires*, telles que les polynucléaires neutrophiles, qui libèrent, parmi d'autres médiateurs de l'inflammation*, de grandes quantités de collagenase, d'élastase, et de hyaluronidase stockées dans leurs granules azurophiles (Vander (1996) J. Clin. Invest. 98: 53-529).

A...

...les situations douloureuses... Les polyphénols et particulièrement les acides hydroxy-cinnamiques dont l'acide chlorogénique ou l'acide caféoylique possèdent des activités anti-inflammatoires* qui agissent contre ses modifications biochimiques, que ce soit dans le cadre de l'allergie* ou non, (Kimura et al. 1984, p. 13-17). En effet, cette classe de molécules a démontré des effets bénéfiques contre les effets délétères... de l'oxygène radicalaire.

Le beurre de karité est obtenu, à partir de noix de l'arbre à karité ou *Butyrospermum parkii* Schuy, selon un procédé classique qui ne fait pas partie de l'invention.

En fonction de la nature du café vert en... sans l'association.

Les effets spécifiques de l'association sur les constituants des tissus de soutien dégradés au cours de l'inflammation* seront rapidement illustrés par trois exemples suivants.

Exemple 3 Radicaux libres et inflammation... Une solution de collagène... d'un système...
...extrait.

Exemple 4 Radicaux libres et inflammation... Les radicaux libres sont naturellement présents dans les tissus.

Cette enzyme agit sur les manifestations tissulaires de l'inflammation* en dégradant la molécule de soutien qu'est l'élastine.

Cette série d'expériences a permis d'identifier une suspension d'élastine et... et la recherche d'effets apaisants cutanés, y compris contre les conséquences des effets néfastes des formes radicalaires de l'oxygène comme, par exemple, l'irritation cutanée, le vieillissement ou le dessèchement prématuré du cuir chevelu, ainsi que pour favoriser la protection des cheveux, du cuir chevelu...

Claim

... vert d'effets apaisants cutanés... Coeur de café... L. Pierre a du beurre de karité ou d'un arbre à karité ou *Butyrospermum*

[illegible]

2. Produit selon 1 caractérise en ce que l'extrait de café contient des polyphénols, notamment des acides hydroxy-cinnamiques et parmi ces derniers...

...et la recherche d'effets apaisants cutanés, y compris contre les conséquences des effets délétères des formes radicalaires de l'oxygène comme, par exemple, l'inflammation cutanée, le vieillissement ou le dessèchement prématuré de la peau, l'apparition des rides, ainsi que pour favoriser la protection des cheveux, du cuir chevelu...

2/6,K/15 (Item from [redacted])
DIALOG(R) File # [redacted] [redacted] s. serv.

00679815

FRACTIONATION PROCESS

FRACTIONATION PROCESS
PROCEDE DE FRACTIONNEMENT

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description:

Claims

Fulltext Word Count: 9830

Publication Year: 1999 ..

Fulltext Availability:

Detailed Description.

Claims

Detailed Desc.

```
... inclusive .
```

The unsaponifiable lipids of shea butter are characterized by a high content of UV-absorbing sterols and natural phytosterols claimed to impose a "sunscreen" effect on damaged skin. The unsaponifiable lipids of shea butter are dominated by a unique high content of sterols, such as stigmasterol, campesterol and...

...well as tocopherols. A number of natural protection against oxidation. An unguent containing rapeseed oil has proven to show an anti-inflammatory effect on irritated skin (Lod6n, M., et al., Effect of topically applied surfactant-irritated skin, British Journal of Dermatology, 1970, 82, 15-20...kernel oil (*Elaeis guineensis*, oleifer), coconut oil (*Cocos nucifera*), babassu oil (*Orbignya martiana*, oleifera), Borneo tallow (*Shorea stenoptera*), mango seed butter (*Balanitoides parkii*), madhuca, mowrah butter (*Morinda morindae*), castor oil (*Ricinus communis*), sal butter (*Shorea robusta*), mango seed oil (*Pandanus indica*), vavada oil, avocado seed oil (*Persea americana*). The water-soluble physical filter in a skin care formulation can be combined with other active ingredients such as alcohols and phytosterols, which have been employed in the past, have an anti-inflammatory action. These substances also have a stabilising effect on cell membranes, which improves the water-binding capacity of the epidermis, giving a desired moistening effect. Tocopherols in combination with phytyl esters are known to show membrane stabilising properties. It is also known that improved water binding capacity of the epidermis. Skin irritation caused by surfactant damage skin is also related to free radicals. An anti-irritant and anti-inflammatory effect of tocopherols can also be attributed to the combination of phytyl esters and tocopherols.

EXAMPLES

EXAMPLES
In the following first titration example, a refined vegetable oil...second,
lower free fatty acid content...the amount of free and
esterified sterols in the product...

Example 5. Fractionation of shea butter

A bleached shea butter (Jatropha curcas* *parkii*) having a melting point of 34°C was first fractionated at +40°C using a temperature gradient of 0.50°C/minute and an acetone/oil ratio... of Tioxide Chemicals Inc., USA.

LIPEX Shea-U is a shea butter fraction prepared according to Example 5 or 6.

BIOLOGICAL TESTS

Test 1. Anti-inflammatory*

The aim of this study was to assess the protective effect of test products on stimulated human dermal keratinocytes (NHEK) by measuring production of IL-8. IL-8 production The IL-8 concentration was determined by protein contents and the... In basal conditions... induced an increase in IL-8 production by approximately... A consistent reduction...

...Canola oil fraction treated cultures and from Hydrocortisone treated cultures were assayed for the presence of IL-8 suggesting that these two products depressed the inflammatory* response induced by croton oil. The Canola oil fraction reduced IL-8 by approximately 24% at C₁, C₂ and C₃.

Hydrocortisone reduced IL-8 by...

...Shea butter fraction at... IL-1α production The intracellular IL-1α concentrations (pg/ml) were corrected by protein contents and the anti-inflammatory* activity (%) was calculated. In basal conditions (without croton oil) croton oil stimulated the production and intracellular accumulation of IL-1α. The intracellular accumulation of IL-1α in croton oil treated cells, the efficiency of the 4 test... could be considered as equivalent and the anti-inflammatory* effect was about 30%. As recorded for IL-8, the anti-inflammatory* effect of Hydrocortisone was higher than that observed with Canola oil fraction. Hydrocortisone reduced IL-1α by approximately 60% at the lowest tested concentration.

In contrast to its effect on IL-8 production, Shea oil fraction reduced the inflammatory* response induced by croton oil. If we considered the protein content... as identical, the efficiency of the 4 tested... could be considered as equivalent and the... is about 25%.

Test 2. UV radiation test... rapeseed oil in vitro The fractionated low-... of Example 1, the canola...

Claim

... fraction... ingredient of a cosmeceutical or pharmaceutical... for... skin moisturizing... anti-inflammatory* properties.

2/6,K/16 (Item 1 from...)

DIALOG(R) File 349:(c) 2001... All rights reserved.

00666964

SKIN LIGHTENING... MAGNESIUM ASCORBYL PHOSPHATE AND UNINONTAN-UM< sup> FORMULATION OF CUCUMBER EXTRACT AND LEMON EXTRA...

COMPOSITION ECLAIRCISSANT... DU PHOSPHATE D'ASCORBYLE DE MAGNESIUM ET L'EXTRAIT... TM < /sup> (FORMULATION D'EXTRAIT DE CON... DE CITRON)

Publication Language: FR

Filing Language: English

Fulltext Available

Details of the... script...

Claims

Fulltext Word...

Fulltext Availability:

Detailed Description

... lead to unwanted freckles or dark spots on the skin, such as senile lentigo, liver spots, melasma, brown or age spots, vitiligo, sunburn pigmentation, post-inflammatory hyperpigmentation due to abrasion, burns, wounds or dermatitis, phototoxic reaction and other similar small, fixed pigmented lesions. It is often desirable to lighten these areas... tinctorius) oil, sage (salvia officinalis) extract, sage (salvia officinalis) oil, salicylic acid, sandalwood (santalum album) oil, serine, serum albumin, sesame (sesamum indicum) oil, shea butter (*butyrospermum parkii*), simethicone, sodium borate, sodium bicarbonate, sodium benzoate, sodium chloride, sodium chondroitin sulfate, sodium citrate, sodium DNA, sodium hexametaphosphate, sodium hyaluronate, the Corite, retinol, retinyl palmitate, RNA, rosemary (rosmarinus officinalis) extract, royal jelly, safflower (carthamus tinctorius) oil, sage (salvia officinalis) extract, sesame (sesamum indicum) oil, shea butter (*butyrospermum parkii*), silica, simethicone, sodium borate, sodium cetearyl sulfate, sodium chloride, sodium dehydroacetate, sodium hyaluronate, sodium hydroxide, sodium PCA, soluble collagen, sorbic acid, sorbitan oleate, sorbitan sesquioleate... sage (salvia officinalis) extract, sage (salvia officinalis) oil, salicylic acid, sandalwood (santalum album) oil, serine, serum albumin, sesame (sesamum indicum) oil, shea butter (*butyrospermum parkii*), silica, simethicone, sodium benzoate, sodium bicarbonate, sodium borate, sodium C12-15 alkyl sulfate, sodium cetyl sulfate, sodium chondroitin sulfate, sodium citrate

2/6,K/17

DIALOG(R) File 349: ... IP... cr ... All ... s. reserv.

00605722

COMPOSITIONS FOR COSMETIC

COMPOSITIONS POLY APPLICAT

Publication Language: English

Filing Language: Eng

Fulltext Availability:

Detailed Descriptic.

Claims

Fulltext Word Count: 345

Publication Year: 1999

Fulltext Available

Detailed

Claims

... Such additional components, e.g., are not limited to, preservatives, abrasives, exfoliants, antiacne agents, anti-aging agents, antibacterials, antiwrinkling, antiwrinkles agents, anticellulites, antidandruff, antifungal, antipruritics*, anti-irritants, antimicrobials, antioxidants, astringents, antiseptics, antistatic agents, astringents, buffers, emulsifiers, additional carriers, chelators, cell stimulants, cleansing agents, etc. SUBSTITUTE SHEET (RULE 26)

conditioners, deodorants, and amino acids, glycylglycine, and retinoids, such as retinoic acid and its derivatives, may be used.

By way of example only, the term "anti-inflammatory*", non-steroidal anti-inflammatory agent (NSAID) should be understood, such as propionic acid derivatives, butyric acids, fenylacetic acid derivatives, biphenylcarboxylic acid derivatives, etc. However, the term is not limited to aspirin...
unpleasant odors. Antidandruff: towards or eliminates dandruff
Depilatory: removes hair. chemical / Antifoam: suppresses foam during

mixing Detergent: a surface-active agent (surfactant) that Anti-
inflammatory: reduces, suppresses, cleans by emulsifying oils and
suspends counteracts in particulate soil Anti-irritant:
reduces, suppresses or eliminates disinfectant: destroys pathogenic
irritation microorganisms and microbials: destroys...acid Black walnut
(Juglans nigra) extract) Gentiana (Echinacea angustifolia) extract
Anticaking Orange blossom extract aluminum starch octenylsuccinate
Pfaffia paniculata. extract... stearate Distarch phosphate Anti-
inflammatory Hydrated silica... polygalacturonic acid Kaolin
Bisabolol Magnesium myristate... Black poplar (Populus nigra)
extract Polyethylene... silylate Butcherbroom...

...collagen amir... amino acids Passion flower
(Passiflora... an... ariana officinalis)
extract... Antimicrobial Shea
butter (*Butyrospermum* parkii*) Benzalkonium chloride Sodium
carboxymethyl beta-glucan Benzoic acid soy (Glycine soja) protein Benzyl
alcohol Stearyl glycol stearate B... chlorophene Stenocalyx micalii
extract 2-Bromo-2-nitro... Salmon (Salmo) egg extract
PPG-5-laureth-5 Sesame... (Sesamum indicum) oil PPG-5 butyl ether Shark
liver oil PPG-5 lanolin... Shea butter (*Butyrospermum* parkii*) PPG-5
pentaerythrityl ether Shea butter (*Butyrospermum* parkii*) extract
PPG-7-buteth-10 Shea butter... Shorea stenoptera butter
PPG-8/SMD1 copolymer Silyl... ethyl ester PPG-9 Sitostearyl
acetate PPG-9...75 hydrolyzed keratin stannate Quaternium-79 hydrolyzed
silk Scalp stimulant... Birch (Betula alba) leaf extract Rice (Oryza
sativa) starch Sebost... saccharina extract Shea butter (
Butyrospermum parkii*)... Hydrolyzed wheat
protein Shorea... Silicane Silica Skin
barrier lipid... S. MFA-stearate...
Carthamus... S. protein
complex Succin... Serum
albumin T... (Sesamum indicum) oil Tromethamine Shea
butter (*Butyrospermum* parkii*) Shea butter (*Butyrospermum* parkii*)
extract Oil absorbent... Shorea stenoptera butter Hydrated silica Silk amino
acids Polymethyl methacrylate Sodium carboxymethyl beta-glucan Silicon
dioxide hydrate Sodium... sulfate Walnut (Juglans...)

Claim

... cosmetic agent... sections or disorders of the
skin is selected... of acidulents, antiacne
agents, anti-aging agents...*, anti irritants,
antioxidants, deodorants... disinfectants, emollients,
exfoliants, humectants... skin conditioners, skin
protectants, skin... agents, suncreening
agents, and... acidulents, anacne
agents, anti... anticaries agents,
anticellulite...*, anti
irritants... antiperspirants,
antiseptics... additional carriers,
chelators, ... conditioners, deodorants,
depilatories, detergents, emollients, emulsifiers...

2/6,K/18 (Item 9 from file 144)

DIALOG(R)File 349... All rts. reserv.

00604811

COMPOSITIONS FOR COSMETIC

COMPOSITIONS UTILIZING

Publication Language: English

Filing Language: English

Fulltext Available

Detailed Description

Claims

Fulltext Word

Publicatic

Fulltext Availability: [Fulltext Available](#)

Detailed Description 201 9

Claims

Detailed Description of each item - 1 page

[illegible]

By way of example, the following are listed: illumination, non steroidal anti-inflammatory agents NSAIDs may be used, such as propionic acid derivatives, acetic acid, benzoic acid derivatives, biphenylcarboxylic acid derivatives, oxycams including but not limited to aspirin... quality and quantity of lather on a foam. Air foam: suppresses foam during mixing. Foamer: a surfactant agent (surfactant) that produces foam: an emulsion of. Anti-inflammatory reduces, suppresses, counteracts inflammation. Anti-irritant reduces, suppresses or prevents irritation. Foam booster see foam booster. Antimicrobial: destroys, inhibits growth of. Fungicide: inhibits... Passiflora flower (Passiflora) extract Hexamidine diisethionate Anticandida extract Candida albicans extract Hinokitiol Cetylamine hydrochloride Lonicera (Lonicera) extract caprifolium extract Butyrospermum (*parkii*) lichen (Usnea) extract beta-glucan Myristic acid Myristic acid ethyl propylenediamine Sodium lauryl sulfate Protein 1 styrene glycol dihydrofluoride stearic acid Pherethyl... indicum) oil Polyglyceryl-2 diisostearate PPG-12-PEG-65 lanolin oil Shark liver oil Glyceryl stearate PPG-12/SMDI Copolymer Shea butter (*Butyrospermum) Polyglyceryl-3 diisostearate. P. oleate PPG-14 butyl ether Shea butter (*Butyrospermum *parkii*) extract Polyglyceryl-3 stearate PPG-15 Stearyl ether Shea butter, ethoxylated lauryl ether PPG-16 Stearyl ether benzoate Shorea stenoptera butyl ether Ricin extract Ricin peptide PEG-3 lauramine diisostearate Ricin extract Ricin peptide PEG-3 stearyl ether benzoate Ricin extract Shea butter (*Butyrospermum *parkii*) PEG-1000 Triethylamine extract Shellac Sodium cocoamphoacetate Vitamin E extract Sodium C12-15 pareth-7 sulfonate Sodium hyaluronate Sodium hyaluronate Sodium... oleate cetyl ether PPG-40 bull ether Quaternium-70 cetyl ether

Quaternium
Rice (Oryza)
Shea butter (*Butyrospermum)
stenoptera butter
Stearamide MEA, S. MEA-st
Lactamide DGA, L. MEA-Sorta
indicum) oil C. oleophan...
ferment Shea b...
protein complex...
parkii) extrac...
Shorea stenopter...
amino acids (Crataegus)

, extract CHEMICAL COMPANY Shorea
Englewood. NJ 07, 631 Silica
e: 201-569-8934 * Fax...arnino acids
nogen Uctic acid Sesame (Sesamum
malate Lactobacillus/whey
Copper aspartate. C.
the Shea butter (*Butyrospermum*
methylsilanol eiastinate
(Gossypium)- oil Lanolin alcohol Silk
tyl PMA...

Claim

... cosmetic agents used for the treatment of disorders of the skin is selected from the group consisting of acidulants, anhydric agents, anti-aging agents, anti-inflammatory agents, anti-irritants, antioxidants, depilator emulsions, disinfectants, emollients, exfoliants, humectants, lubricants, moisturizers, skin conditioners, skin

This study (Konning) has been

...oil free formulation, it has a good spreadability and quick rub-in properties.

Following is a list of Shea butter regulatory agreements:

Shea butter

INCI (*Butyrospermum parkii*)
CAS no. 9 980 - 8
Europe ELINCS no. 323 51 7
Japan CLS no. 523 110

DEFINING (

Shea butte

?